Haverford Trust Co Takes $2.24 Million Position in Danaher Corporation $DHR

Key Points

• Haverford Trust Co. bought 11,763 Danaher shares during the second quarter, valued at approximately $2.24 million. Institutional investors and hedge funds collectively own 79.05% of DHR stock.
• Danaher’s latest quarterly results exceeded expectations, with EPS of $1.94 versus the $1.85 consensus and revenue of $6.26 billion, up 5.5% year over year.
• Analyst sentiment remains positive, with Danaher carrying a “Moderate Buy” consensus rating and an average price target of $228.91, compared with a recent share price of $219.42.

Haverford Trust Co purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,763 shares of the conglomerate's stock, valued at approximately $2,241,000.

A number of other large investors have also modified their holdings of DHR. Main Street Group LTD bought a new stake in Danaher in the 1st quarter valued at about $25,000. N.E.W. Advisory Services LLC bought a new position in Danaher in the 2nd quarter worth about $25,000. JPL Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth about $25,000. WFA of San Diego LLC acquired a new stake in shares of Danaher in the second quarter valued at approximately $26,000. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Danaher in the fourth quarter valued at approximately $27,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Trading Up 1.6%

Danaher stock opened at $219.42 on Friday. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock has a market capitalization of $154.25 billion, a PE ratio of 38.97, a price-to-earnings-growth ratio of 2.72 and a beta of 0.78. The firm has a 50 day simple moving average of $195.80 and a 200-day simple moving average of $192.61.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analysts' expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm's quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.77 earnings per share. As a group, equities research analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on DHR. Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a "buy" rating for the company in a research report on Wednesday, July 22nd. Royal Bank Of Canada raised their target price on Danaher from $200.00 to $215.00 and gave the company an "outperform" rating in a research report on Wednesday, July 22nd. Weiss Ratings raised Danaher from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, July 15th. HSBC reduced their price target on Danaher from $270.00 to $230.00 and set a "buy" rating for the company in a research report on Wednesday, June 3rd. Finally, Piper Sandler assumed coverage on Danaher in a report on Thursday, June 11th. They set a "neutral" rating and a $200.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Danaher currently has an average rating of "Moderate Buy" and an average target price of $228.91.

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source